AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14684762
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of flaxseed
Trial: 14684762
Drug: 28 g
RxNorm normalized name: SM Syringe 28 g, 0.5cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 g of wheat bran
Trial: 14684762
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of flaxseed plus 28 g of wheat bran
Trial: 2859739
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg (control)
Trial: 30130991
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: B + physical and psychological approaches to LBP treatment
Trial: 22017169
Drug: Osteopontin levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopontin levels in women (mean ± SD: 51.7 ± 16.0 μg/mL)
Trial: 10757134
Drug: 0.62 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.62 g/kg of alcohol
Trial: 9282804
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of acetazolamide (Diamox) intravenous injection
Trial: 29226816
Drug: Subcutaneous furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous furosemide (SC)
Trial: 24923685
Drug: 91-day extended
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 91-day extended regimen combined oral contraceptive (150 μg levonorgestrel [LNG]/30 μg ethinylestradiol [EE] for 84 days, followed by 10 μg EE for seven days)
Trial: 24923685
Drug: Traditional 21/7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional 21/7 regimen (21 days 150 μg LNG/30 μg EE)
Trial: 21702861
Drug: Routine prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine prevention (six-hourly repositioning using 90° lateral rotation) (control group)
Trial: 12568305
Drug: Granisetron alone
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron alone (G group)
Trial: 11594407
Drug: Cerivastatin 0.8
RxNorm normalized name: cerivastatin 0.8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin 0.8 mg
Trial: 11594407
Drug: Cerivastatin 0.4
RxNorm normalized name: cerivastatin 0.4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin 0.4 mg
Trial: 9352727
Drug: Intensive neurodevelopmental
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive neurodevelopmental therapy (NDT) plus casting
Trial: 24986270
Drug: Cure‐allergic‐rhinitis Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cure‐allergic‐rhinitis Syrup (CS)
Trial: 7635028
Drug: Oral formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral formulations of mesalazine
Trial: 2658438
Drug: Insulin coma
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin coma (IC) after pharmacotherapy with mageptil, chlorpromazine, melipramine
Trial: 2658438
Drug: Insulin coma
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin coma (IC) after pharmacotherapy with haloperidol, triphtazin, amitriptyline
Trial: 2658438
Drug: Insulin coma
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin coma (IC) after benzodiazepines
Trial: 2658438
Drug: Insulin coma
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin coma (IC) therapy
Trial: 2658438
Drug: Insulin coma
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin coma (IC) in drug-free patients
Trial: 28622178
Drug: Lumbar Epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar Epidural (LE) with 0.125% bupivacaine and 50 μg fentanyl
Trial: 20418251
Drug: General practitioner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General practitioner treatment as usual (n=100)
Trial: 27937053
Drug: Ticagrelor 180
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 180 mg single oral dose
Trial: 15613405
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose testosterone administration
Trial: 7867678
Drug: mizolastine 20
RxNorm normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mizolastine 20 mg
Trial: 7867678
Drug: mizolastine 5
RxNorm normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mizolastine 5 mg
Trial: 7867678
Drug: clemastine 2
RxNorm normalized name: clemastine 2 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clemastine 2 mg
Trial: 2572902
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg pamidronate as a single intravenous infusion
Trial: 2572902
Drug: Etidronate as
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etidronate as three infusions of 7.5 mg/kg per day for three consecutive days
Trial: 792994
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg terbutaline inhaled via IPPB
Trial: 792994
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg terbutaline inhaled via IPPB
Trial: 31823444
Drug: Risperidone (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (2, 4 or 6 mg/day)
Trial: 3165190
Drug: Chemomechanical preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemomechanical preparation
Trial: 15347339
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream (three times weekly)
Trial: 15347339
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream (five times weekly)
Trial: 9568413
Drug: Neoral at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoral at 2.5 mg/kg/day or equivalent to pre-conversion SIM dosage
Trial: 403149
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of tritium-labeled ergot alkaloids
Trial: 27583439
Drug: Lipid solutions
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid solutions delivered separately (Group 1)
Trial: 27583439
Drug: Lipid solutions
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid solutions in mixture with TPN solutions (Group 2)
Trial: 15520986
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza vaccine (intramuscular administration)
Trial: 8418313
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy followed by standard therapy with surgery and/or radiation
Trial: 3080575
Drug: Ibuprofen (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (25 mg/kg/day)
Trial: 3080575
Drug: Indomethacin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (2 mg/kg/day)
Trial: 2682120
Drug: Aminophylline (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (6 mg/kg over 15 minutes)
Trial: 30847474
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg maintenance dose starting at Week 6
Trial: 28100440
Drug: Web Behavior
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Web Behavior Change Program for Activity (Web‐BCPA) in combination with multimodal rehabilitation (MMR)
Trial: 26286532
Drug: Post-treatment pain
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment pain alone
Trial: 26286532
Drug: Pre-treatment predictor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment predictor models
Trial: 14634864
Drug: Cyclophosphamide, 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide, 90 mg/m(2)/day for 42 days
Trial: 9631379
Drug: NSAID (non-steroidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID (non-steroidal anti-inflammatory drugs)
Trial: 2591089
Drug: Oil-in-water emulsion
RxNorm normalized name: mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil-in-water emulsion applied twice daily for 7 days
Trial: 26066384
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg intravenous
Trial: 16765179
Drug: alfuzosin 10
RxNorm normalized name: Alfuzosin 10mg Oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfuzosin 10 mg daily + tadalafil 20 mg
Trial: 16765179
Drug: alfuzosin 10
RxNorm normalized name: Alfuzosin 10mg Oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfuzosin 10 mg daily + placebo
Trial: 11903327
Drug: Different classes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different classes of drug for blood pressure lowering
Trial: 17314584
Drug: Diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 75 mg b.i.d.
Trial: 8866631
Drug: Urapidil (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil (60 mg)
Trial: 31044510
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement combined with maxillary sinus floor elevation utilizing the transalveolar approach and nonsubmerged healing
Trial: 31044510
Drug: Delayed implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed implant placement combined with maxillary sinus floor elevation utilizing the transalveolar approach and nonsubmerged healing
Trial: 28467771
Drug: Reduction of
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of CTC enumeration after two cycles of chemotherapy
Trial: 9972339
Drug: Topical carbonic
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical carbonic anhydrase inhibitor (dorzolamide) in association with beta-blockers
Trial: 9972339
Drug: Topical carbonic
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical carbonic anhydrase inhibitor (dorzolamide) in association with beta-blockers and miotics
Trial: 3134314
Drug: Nitroglycerin ointment
RxNorm normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin ointment placed on the upper arm
Trial: 3134314
Drug: Nitroglycerin ointment
RxNorm normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin ointment placed on the chest
Trial: 3134314
Drug: Nitroglycerin ointment
RxNorm normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin ointment placed on the pelvis
Trial: 8661572
Drug: No-drug control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-drug control group
Trial: 10390554
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of dicyclomine chlorhydrate
Trial: 10390554
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of dicyclomine chlorhydrate
Trial: 8654625
Drug: GnRH analogue
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH analogue treatment (6 SC implants of 3.6 mg goserelin acetate depot every 28 days for 6 months)
Trial: 8485328
Drug: Total nutrient
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total nutrient admixture (TNA) at the rate of 4‐5 g lipid/h for 5‐9 days (mean 6.7 days)
Trial: 22827935
Drug: Rehabilitative sports
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitative sports group exercise program for prostate cancer patients, conducted for 15 months starting 8-12 weeks after prostatectomy or combination therapy.
Trial: 21375023
Drug: Diovan (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diovan (80 mg)
Trial: 18037738
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (aspirin, clopidogrel, cilostazol)
Trial: 17697815
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (aspirin and clopidogrel)
Trial: 2548967
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ultramicronized griseofulvin
Trial: 1099692
Drug: Three antimalarial
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three antimalarial drugs
Trial: 26641243
Drug: GM-CSF (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF (250 μg/m2/d)
Trial: 26641243
Drug: Influenza vaccination
RxNorm normalized name: Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine Injection [PedvaxHIB]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccination (Mutagrip 0.5 ml/d)
Trial: 3721047
Drug: Lumbar epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar epidural analgesia (L.E.A.)
Trial: 16087821
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus ergocalciferol (1000 IU) and calcium (1200 mg)
Trial: 16087821
Drug: Risedronate sodium
RxNorm normalized name: Risedronate Sodium
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Risedronate sodium (2.5 mg daily) plus ergocalciferol (1000 IU) and calcium (1200 mg)
Trial: 12700718
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg diazepam (DZP)
Trial: 10582134
Drug: VNR 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VNR 25 mg/m2 + CP 60 mg/m2
Trial: 31743184
Drug: Incentive-based game
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incentive-based game therapy
Trial: 23174912
Drug: XELOX plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOX plus bevacizumab (6 cycles) followed by either single-agent bevacizumab or XELOX plus bevacizumab until disease progression
Trial: 26094974
Drug: Sitagliptin 25
RxNorm normalized name: SITagliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 25 mg once daily
Trial: 3346483
Drug: 351 mg
RxNorm normalized name: Erzofri 351 MG in 2.25 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 351 mg of theophylline in 35 mg of ethylenediamine (TE351)
Trial: 3346483
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of theophylline in 300 mg of propxyphylline and 300 mg of diprophylline (TPD)
Trial: 29270914
Drug: Interscalene block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interscalene block (ISB) with 20 mL of levobupivacaine 0.25% and epinephrine 5 µg·mL‐1
Trial: 29270914
Drug: Combined infraclavicular-suprascapular
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined infraclavicular-suprascapular blocks (ICB-SSB) with 20 mL of levobupivacaine 0.25% and 10 mL for SSB
Trial: 26922549
Drug: Intensive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive statin treatment (rosuvastatin 20‐40 mg daily)
Trial: 26922549
Drug: Less aggressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less aggressive statin treatment (simvastatin 20‐40 mg daily)
Trial: 22790642
Drug: Once-daily tadalafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily tadalafil 5 mg (with possible down-titration to 2.5 mg)
Trial: 18214942
Drug: Inhaled furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled furosemide (IF) 2 mg/kg nebulized by hood three times daily
Trial: 18214942
Drug: Placebo nebulized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nebulized by hood three times daily
Trial: 18214942
Drug: Inhaled furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled furosemide (IF)
Trial: 17064621
Drug: RFA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RFA therapy combined with suture and ligation surgery (SL group, n = 15)
Trial: 17064621
Drug: RFA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RFA therapy without suture and ligation surgery (non-SL group, n = 15)
Trial: 1829902
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg UK 79300
Trial: 1829902
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg UK 79300
Trial: 10333643
Drug: Oral transmission
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmission of strongyloidiasis
Trial: 7710623
Drug: Bone graft
RxNorm normalized name: Bone graft material
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone graft and implant placement in the routine group (20 patients)
Trial: 7710623
Drug: Bone graft
RxNorm normalized name: Bone graft material
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone graft and implant placement in the development group (10 patients)
Trial: 7710623
Drug: Bone graft
RxNorm normalized name: Bone graft material
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone graft and implant placement (both groups)
Trial: 901625
Drug: BM 15.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BM 15.075 (0.2 g t.i.d.)
Trial: 27151908
Drug: Standard syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard syringe injection
Trial: 27151908
Drug: Both injection
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both injection techniques
Trial: 20410150
Drug: Sit-to-stand training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sit-to-stand training (15 minutes each session, in addition to 30 minutes of general physical therapy three times a week for four weeks)
Trial: 16310974
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus CM
Trial: 8981202
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg three times daily)
Trial: 26194935
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg daily for 28 days
Trial: 20515216
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (psychotherapy and pharmacotherapy)
Trial: 20515216
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral analysis system of psychotherapy (monotherapy)
Trial: 20515216
Drug: Nefazodone (monotherapy)
DrugBank: Nefazodone (DB01149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nefazodone (monotherapy)
Trial: 16862549
Drug: Low-energy laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy laser intervention applied for 5 days following the start of chemotherapy.
Trial: 12132977
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily for 7 weeks)
Trial: 7572947
Drug: B subunit‐killed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B subunit‐killed whole cell (BS‐WC) or killed whole cell‐only (WC) oral cholera vaccines
Trial: 1981748
Drug: mifentidine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mifentidine 20 mg at night
Trial: 6452464
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of oral tetracycline twice daily
Trial: 25087839
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) 25 mg BIW during Cycle 2 after relapse
Trial: 2576322
Drug: Caffeine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (10 mg/kg)
Trial: 15076238
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (r-hGH) at a dose of 4 mg daily (DD)
Trial: 15076238
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (r-hGH) at a dose of 4 mg on alternate days (AD)